Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of Drug Resistant TB - Questions

Published byἨλίας Μαρκόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Treatment of Drug Resistant TB - Questions"— Presentation transcript:

1 Treatment of Drug Resistant TB - Questions
Nesri Padayatchi

2 Isoniazid mono- resistance is usually treated with
Rifampicin, Isoniazid, pyrazinamide and Ethambutol in the intensive phase and then only Rif and INH in the continuation phase Rifampicin, Isoniazid, Pyrazinamide and Ethambutol for 6-9 months Rifampicin, Moxifloxacin, Kanamycin for Rifampicin, INH and Kanamycin Rifampicin, INH, Moxifloxacin and Kanamycin Correct answer is 2

3 MDRTB is TB that is resistant to…
Rifampicin At least Rifampicin and INH Rifampicin, INH and Moxifloxacin Rifampicin, INH and Kanamycin Rifampicin, INH, Moxifloxacin and Kanamycin Correct answer is 2

4 Standard MDR-TB treatment is usually
Streptomycin, Moxifloxacin, Ethionamide Terizidone, Pyrazinamide, Kanamycin, Moxifloxacin, Ethionamide Terizidone, Pyrazinamide, Capreomycin, Moxifloxacin, Ethionamide Terizidone, Pyrazinamide, 2 is correct

5 An inhA mutation confers resistance to which drug?
Moxifloxacin Rifampicin High Dose INH Ethionamide Terizidone 4 is correct

6 A katG mutation confers resistance to which drug?
Moxifloxacin Rifampicin High Dose INH Ethionamide Terizidone 3 is correct

Download ppt "Treatment of Drug Resistant TB - Questions"

Similar presentations

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.
Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.

Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.
TREATMENT OF TUBERCULOSIS, 2003

TREATMENT OF TUBERCULOSIS, 2003
Latent Infection of Tuberculosis in China HUASHAN HOSPITAL, FUDAN UNIVERSITY, Shanghai, China Wenhong Zhang, M.D & PhD.

Latent Infection of Tuberculosis in China HUASHAN HOSPITAL, FUDAN UNIVERSITY, Shanghai, China Wenhong Zhang, M.D & PhD.
Occupational MDR-TB & me Reaching Zero TB Deaths and Zero New TB Infections Satellite Symposium, Kuala Lumpur, Malaysia Dalene and Arne von Delft13 November.

Occupational MDR-TB & me Reaching Zero TB Deaths and Zero New TB Infections Satellite Symposium, Kuala Lumpur, Malaysia Dalene and Arne von Delft13 November.
Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.

Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.
Adverse Drug Reactions to Anti-TB drugs Dr M A Jalil Chowdhury Professor of Medicine Bangabandhu Sheikh Mujib Medical University.

Adverse Drug Reactions to Anti-TB drugs Dr M A Jalil Chowdhury Professor of Medicine Bangabandhu Sheikh Mujib Medical University.
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
7. Anti-TB regimen in special situations of liver disease, renal impairment, and pregnancy.

7. Anti-TB regimen in special situations of liver disease, renal impairment, and pregnancy.
XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,

XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,
Anti-tuberculous drugs. Mycobacteria Slow-growing bacillusDormant forms in macrophages.

Anti-tuberculous drugs. Mycobacteria Slow-growing bacillusDormant forms in macrophages.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Richard Kohler, MD TB Consultant, Indiana State Department of Health Division of Infectious Diseases Indiana University School of Medicine.

Richard Kohler, MD TB Consultant, Indiana State Department of Health Division of Infectious Diseases Indiana University School of Medicine.
Antimycobacterial drugs Tuberculosis Treatment of mycobacterial infections is complicated due: Limited information regarding antimycobacterial drug actions.

Antimycobacterial drugs Tuberculosis Treatment of mycobacterial infections is complicated due: Limited information regarding antimycobacterial drug actions.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated 10-15 million persons.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
HIV-TB Model: The Botswana experience By E.M. Lungu (UB) M. Kgosimore (BCA) F. Nyabadza (UB) Modeling Disease in Africa Workshop 25 – 27 June 2007, Stellenbosch,

HIV-TB Model: The Botswana experience By E.M. Lungu (UB) M. Kgosimore (BCA) F. Nyabadza (UB) Modeling Disease in Africa Workshop 25 – 27 June 2007, Stellenbosch,
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant

MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
1 Introduction to Drug-Resistant TB Session 2. USAID TB CARE II PROJECT Classification of drug-resistant TB “Drug-resistant TB” is a general term to describe.

1 Introduction to Drug-Resistant TB Session 2. USAID TB CARE II PROJECT Classification of drug-resistant TB “Drug-resistant TB” is a general term to describe.
Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.

Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.
Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February 2015 - Yerevan New treatments and approaches.

Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February Yerevan New treatments and approaches.

Similar presentations

Ads by Google